Product Description
CK2α1 (Casein kinase 2 alpha 1), also known as CSNK2A1, is a member of the serine/threonine kinase family that plays a pivotal role in cell survival, proliferation, apoptosis, and circadian rhythm regulation. As the catalytic subunit of protein kinase CK2, CK2α1 forms a stable tetrameric complex with CK2β regulatory subunits and phosphorylates a wide range of downstream substrates involved in transcription, translation, and signal transduction, functioning independently of second messengers. Beyond its essential physiological functions in cellular homeostasis, dysregulation of CK2α1—including overexpression, constitutive activation, and aberrant substrate phosphorylation—is frequently observed in various human cancers (such as leukemia, breast cancer, prostate cancer, and glioblastoma), as well as in inflammatory diseases, viral infections, and neurodegenerative disorders, making it a highly validated target for cancer therapy and drug discovery.
Screeningbio’s CK2α1 Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying CK2α1 kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: CK2α1 catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the CK2α1 kinase.
Data